Similar results were found on comparing samples of healthy subjects with those of non LT fibrotic GDC-0449 cost patients, indicating that our findings were not related either LT or HCV infection. The 5925 m/z
peak was also absent or expressed at very low intensity in the LT patients of the confirmation group. Identification of this protein peak showed more than a 99% coincidence with a C-terminal fragment of the fibrinogen α chain. In conclusion, by assessing protein profiles in LT patients with fibrosis recurrence we identified a 5.9 kDa C-terminal fragment of the fibrinogen α chain as a serum bio-marker of early fibrogenic processes in patients with liver disease. Disclosures: Xavier Forns – Consulting:
Tibotec/Jansen, MSD, Boheringher Ingelheim; Grant/Research Support: Roche, MSD, Gilead Wladimiro Jiménez-Grant/Research Support: Ferring Belnacasan order Research Institute The following people have nothing to disclose: Santi Marfa, Gonzalo Crespo, Gregori Casals, Manuel Morales-Ruiz, Miquel Navasa Long term suppression of HBV DNA with TDF results in a reduction in liver fibrosis and the regression of histologic cirrhosis (Lancet 201 3;385:468). Morphometric quantitative collagen (MQC) may be a more accurate way to measure changes in liver fibrosis than traditional fibrosis scoring systems. This study assessed the change in MQC over 5 years in patients with CHB treated with TDF. Methods: Liver biopsy slides from the 344 patients who had liver
biopsies at baseline (BL) and weeks 48 and 240 in the TDF phase 3 trials were stained with picosir-ius red. Digital image analysis was used to calculate the relative collagen content of each biopsy. Biopsy slides with less than 5mm2 of tissue and those with <3% collagen at BL were excluded. Change in collagen over time was MCE公司 analyzed using Wilcoxon Sign Rank Test and comparisons between patients with and without persistent cirrhosis were assessed with the Wilcoxon Rank Sum Test. Results: A total of 765 liver biopsy slides were available, and of these 600 were of adequate quality for assessment. The mean and median collagen decreased significantly over time (Figure 1a). In patients with cirrhosis at BL, the mean collagen declined from 7.78% at BL to 4.07% at year 5 (p < 0.0001). Patients with persistent cirrhosis by Ishak stage had higher mean collagen at BL than those who had regression of cirrhosis (Figure 1b), and both groups had a reduction in mean collagen over time. Patients with regression of cirrhosis demonstrated a 42% mean reduction in collagen compared with 17% in those with persistent cirrhosis by Ishak stage. Conclusions: Long term virologic suppression in CHB patients was associated with a significant reduction in MQC regardless of BL Ishak fibrosis stage. The decline in collagen was apparent by week 48.
Related posts: